Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00043316 · ClinicalTrials.gov registry record · Phase 1

Interferon Gamma-1b by Inhalation for the Treatment of Patients With Cystic Fibrosis

A Phase 1 study of Cystic Fibrosis, sponsored by InterMune.

Completed
Registry status
Phase 1
Development phase
66
Enrollment target
17
Study locations

NCT00043316: Completed Phase 1 study of Cystic Fibrosis, sponsored by InterMune.

NCT00043316 is a Phase 1 study of Cystic Fibrosis that has completed, run by InterMune. The registered enrollment target is 66 participants, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (63% lower). The trial reports 17 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00043316, a Phase 1 study of Cystic Fibrosis, has completed, sponsored by InterMune.

COMPLETED
Registry status
Phase 1
Development phase
66 participants
Enrollment target
17
Study locations

Study Summary

The purpose of this research study is to evaluate the safety and effectiveness of Interferon gamma-1b (IFN-g 1b) on lung function when given to patients with cystic fibrosis by inhalation (breathed into the lungs) three times a week for 12 weeks. The FDA has not approved Interferon gamma-1b for use with cystic fibrosis patients, which is the condition being examined in this study.

Conditions Studied

Cystic Fibrosis

Interventions

  • DRUG interferon gamma-1b

Study Locations (17)

California

  • - Palo Alto
  • - Sacramento
  • - San Diego
  • - San Francisco

Florida

  • - Daytona Beach
  • - Orlando

Texas

  • - Lackland Air Force Base
  • - Tyler

Alabama

  • - Birmingham

Arizona

  • - Phoenix

Colorado

  • - Denver

Illinois

  • - Chicago

Louisiana

  • - New Orleans

Trial Details

FieldValue
Enrollment Target 66 participants
Start Date 2001-02
Est. Completion 2002-10
Phase Phase 1
InterMune

11 total trials

What the finished NCT00043316 record still lists

NCT00043316 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 66 participants, a relatively small participant target, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (63% lower).

The record links to 1 condition, with Cystic Fibrosis appearing as the primary indexed condition, and to 1 intervention - of which interferon gamma-1b is the first listed.

NCT00043316 lists 17 locations in 12 states (California, Florida, Texas).

Frequently Asked Questions

What is clinical trial NCT00043316 about?

NCT00043316 is a clinical study titled "Interferon Gamma-1b by Inhalation for the Treatment of Patients With Cystic Fibrosis". The purpose of this research study is to evaluate the safety and effectiveness of Interferon gamma-1b (IFN-g 1b) on lung function when given to patients with cystic fibrosis by inhalation (breathed into the lungs) three times a week for 12 weeks. The FDA has not approved Interferon gamma-1b for use...

What is the current status of trial NCT00043316?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 66 participants. The study started on 2001-02. Estimated completion is 2002-10.

What conditions does trial NCT00043316 study?

This clinical trial studies the following conditions: Cystic Fibrosis.

What interventions are being tested in trial NCT00043316?

The interventions under investigation include: interferon gamma-1b (DRUG).

Who is sponsoring clinical trial NCT00043316?

This trial is sponsored by InterMune, which has 11 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00043316 being conducted?

This trial has 17 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Cystic Fibrosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00043316's enrollment target sits among peer trials

66 76th of 169 higher than 94 of 169 other Cystic Fibrosis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cystic Fibrosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02584244 · 66 participants · Phase 1

    Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers

  • NCT03067051 · 66 participants · Phase 1

    Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System

  • NCT03754725 · 66 participants · Phase 1

    Ferritin and Iron Burden in SAH sIRB

  • NCT03875378 · 66 participants · Phase 2

    Transdermal Estrogen in Women With Anorexia Nervosa

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00043316, the US trial registry maintained by the National Library of Medicine. NCT00043316 (small enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.